Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease.

Abstract

Pooled data from randomized clinical trials on lipid-lowering therapy have provided valuable information and clinical insights. Although cardiovascular disease is a common cause of death, mortality data have rarely been prominent in key lipid trials. The 4S, LIPID and HPS trials were the first to demonstrate a reduction in overall mortality. Lower- versus higher-intensity statin trials and non-statin lipid-lowering trials with ezetimibe and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors proved that additional lipid lowering significantly reduces the occurrence of cardiovascular events. However, only the ODYSSEY OUTCOMES trial showed a reduction in all-cause mortality. The aim of the present narrative review was to contrast these results with those of other key lipid trials: those assessing statins compared with placebo, those evaluating intensive- versus moderate-intensity lipid-lowering therapy and, finally, those investigating non-statin lipid-lowering therapies.

• Authors: Juan Pedro-Botet, Jose López-Miranda, Lina Badimón, Fernando Civeira, Carlos Guijarro, Jesús Millán, Jose M Mostaza, Xavier Pintó, Pedro Valdivielso, Luis Masana, Expert group from the Spanish Arteriosclerosis Society
• Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions (Am J Cardiovasc Drugs) Vol. 20 Issue 4 Pg. 325-332 (Aug 2020) ISSN: 1179-187X [Electronic] New Zealand
• PMID: 31650523 (Publication Type: Journal Article, Review)

Chemical References

• Cholesterol, LDL
• Lipids
• Proprotein Convertase 9
• Ezetimibe

Topics

• Cardiovascular Diseases (blood, mortality)
• Cholesterol, LDL (blood)
• Ezetimibe (therapeutic use)
• Humans
• Lipids (blood)
• Proprotein Convertase 9 (metabolism)
• Randomized Controlled Trials as Topic
• Secondary Prevention (methods)